Madrigal Pharmaceuticals, Inc. MDGL Business Segments — Cost of Sales
Discontinued — last reported Q3 '25
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Madrigal Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingCostsAndExpenses.
The official record: Madrigal Pharmaceuticals, Inc.’s 10-Q, filed November 4, 2025, on SEC EDGAR. View the filing →
Ask your AI about Madrigal Pharmaceuticals, Inc.'s business segments — cost of sales.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Madrigal Pharmaceuticals, Inc.'s business segments — cost of sales?
- Madrigal Pharmaceuticals, Inc. (MDGL) reported business segments — cost of sales of $18.12M in Q3 2025.
- What does business segments — cost of sales mean?
- The direct costs incurred to manufacture and deliver the products sold by the segment.
- How do you interpret business segments — cost of sales?
- A lower ratio relative to revenue indicates better manufacturing efficiency or higher pricing power, while an increase may signal rising production costs or supply chain inefficiencies.
- How does business segments — cost of sales compare across companies?
- Comparable to Cost of Goods Sold (COGS) in other pharmaceutical companies, where margins are heavily influenced by manufacturing complexity and patent protection.